Ro-3306

Name: Ro-3306
Brand: Selleck Chemicals
SKU: S7747
Rating: 5 (80 reviews)

For research use only.

Catalog No.S7747

80 publications

CAS No. 872573-93-8

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.

Selleck's Ro-3306 has been cited by 80 publications

Science, 2021, 371(6535)eabc5386

PubMed: 33542149 ( click the link to review the publication )

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3760

PubMed: 34145295 ( click the link to review the publication )

Nat Struct Mol Biol, 2021, 28(6):487-500

PubMed: 34117478 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108840

PubMed: 33730584 ( click the link to review the publication )

PLoS Pathog, 2021, 17(5):e1009580

PubMed: 33974675 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1540.2020

PubMed: 33941591 ( click the link to review the publication )

J Cancer, 2021, 12(8):2206-2215

PubMed: 33758599 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(13)6943

PubMed: 34203295 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(11)5706

PubMed: 34071893 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00485-3

PubMed: 33895139 ( click the link to review the publication )

STAR Protoc, 2021, 2(3):100495

PubMed: 34195669 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: None ( click the link to review the publication )

EMBO J, 2021, e106336

PubMed: 33595114 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: N/A ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-0357-y

PubMed: 32561861 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4338

PubMed: 32859893 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Genes Dev, 2020, 1;34(9-10):650-662

PubMed: 32217664 ( click the link to review the publication )

EMBO Rep, 2020, e48686

PubMed: 32484300 ( click the link to review the publication )
Cancer Res, 2020, 20 pii: canres 883 2019

PubMed: 32312836 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00641-7

PubMed: 33110216 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1637

PubMed: 32575711 ( click the link to review the publication )

Cells, 2020,

PubMed: 32846968 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12882

PubMed: 33320980 ( click the link to review the publication )

Cell Discov, 2020, 28;6:26

PubMed: 32351706 ( click the link to review the publication )

Cell Transplant, 2020, 29:963689720950226

PubMed: 32841050 ( click the link to review the publication )

Gland Surg, 2020, 9(2):558-574

PubMed: 32420291 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):180

PubMed: 32152291 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32033461 ( click the link to review the publication )

J Cell Sci, 2020, 133(14):jcs243857

PubMed: 32591484 ( click the link to review the publication )

Neuroendocrinology, 2020, 10.1159/000509865

PubMed: 32615570 ( click the link to review the publication )

Viruses, 2020, 6;12(3):289

PubMed: 32155766 ( click the link to review the publication )

Development, 2020, 147(13):dev184838

PubMed: 32620578 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Mol Cell, 2019, 75(2):267-283

PubMed: 31202576 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2253

PubMed: 31138795 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz602

PubMed: 31291454 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1915108116

PubMed: 31712441 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )
Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Cell Rep, 2019, 26(4):955-968.e3

PubMed: 30673617 ( click the link to review the publication )

Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

FASEB J, 2019, 33(4):5334-5349

PubMed: 30668924 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4511

PubMed: 30375385 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2171-2178

PubMed: 29438989 ( click the link to review the publication )

J Biol Chem, 2018, 293(40):15524-15537

PubMed: 30135207 ( click the link to review the publication )

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30545129 ( click the link to review the publication )

Cancer research, 2018, 10.1158/0008-5472.CAN-17-2288

PubMed: ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201801369R

PubMed: 30496702 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

Elife, 2017, 6e30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

EBioMedicine, 2017, 19:18-30

PubMed: 28434945 ( click the link to review the publication )

Sci Rep, 2017, 7:44464

PubMed: 28290553 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(20)

PubMed: 28760773 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0149099

PubMed: 26881434 ( click the link to review the publication )

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
KB-3-1 adenocarcinoma cell line	MVjxTHRUKGG\|c3H5		NHPp[XRRNWeueXPvdJJwfGWrbjDzeYJ{fHKjdHXzJIll\W62aX\p[YQhcW5iS1KtN{0yKGGmZX7vZ4Fz[2mwb33hJINmdGxibHnu[UwheUiWUzD0bIVz[XCndYTpZ{BtcWK{YYL5JJNkemWnbh?=	NXn0fWJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1NVUzQDRpPkOxOVE2Ojh2PD;hQi=>
human H460a cells	NGLNZ4ZRem:uaX\ldoF1cW:wIHHzd4F6		MoH3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKNE[wZUBk\WyuczygTWM2OD1zLkC0JO69VQ>?	NGTsO249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human MDA435 cells	M{XqTnBzd2yrZnXyZZRqd25iYYPzZZk>		NGm2fnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERVQ{PSClZXzsd{whUUN3ME2xMlE1KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyM{SyNUc,OTd\|MEO0NlE9N2F-
human HCT116 cells	NHPyU3RRem:uaX\ldoF1cW:wIHHzd4F6		M{fZUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzMEBKSzVyPUGuNVQh\|ryP	NGTqNVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human RKO cells	MUPQdo9tcW[ncnH0bY9vKGG\|c3H5		NV7xOJROSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDST28h[2WubIOsJGlEPTB;MjFOwG0>	NUXufGtCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezNFM1OjFpPkG3N\|A{PDJzPD;hQi=>
human SW480 cells	NWCxWFhZWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NETYZoVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOFgxKGOnbHzzMEBKSzVyPUKuNkDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyM{SyNUc,OTd\|MEO0NlE9N2F-
human SJSA1 cells	NYHjNHZ6WHKxbHnm[ZJifGmxbjDhd5NigQ>?		Mkj0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSmPBNUBk\WyuczygTWM2OD12LkW1JO69VQ>?	Mn3tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MEO0NlEoRjF5M{CzOFIyRC:jPh?=
human HCT116 cells	NXnpXlVXS3m2b4TvfIlkyqCjc4PhfS=>	M1XkW\|Uh\GG7cx?=	NX23bYQ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[XoxvJygTWM2OD1\|LkKg{txO	M{LpUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{K2NVY5Lz5{MkOyOlE3QDxxYU6=
NCI-SNU-1	NIDFTVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NETPcpdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD63N\|A6PSEQvF2u	NIXqfZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
H4	M3;vRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIDlU3FKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlE2QDd3IN88UU4>	M3PpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
PA-1	NW\ZXYRyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4TVcGlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4zOjZ3NDFOwG0v	MmHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
T98G	NUPteXlwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmXXTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlM3QDF{IN88UU4>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SW1710	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3O0OmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjZzNEC4JO69VS5?	NIXmdmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
U251	MnTQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1vSdWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU43Ozd5MTFOwG0v	NUnlXpRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
ALL-PO	M4HxUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2LTWmlvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjlyOEGzJO69VS5?	NX;6dFBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SK-N-DZ	MmOxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnvtTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVTaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjBzOEe2JO69VS5?	NWrOZYl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A4-Fuk	NX;JVZc3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk4xPTZyNDFOwG0v	NF:0OVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
639-V	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MljJTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk4zPzV\|NzFOwG0v	NYPVfHNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
Hs-578-T	M1Lofmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVTKUGdsUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O\|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj6yO\|c6QSEQvF2u	NIrwUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
UM-UC-3	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnHkTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjd\|OUO2JO69VS5?	NULwV2lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
BPH-1	MnnmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlX2TY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk46PzR3NTFOwG0v	M3f0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
5637	NVHhNWM1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOuNFg2OzJizszNMi=>	M1;xTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
8-MG-BA	NIfrV3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvOTRyNEmg{txONg>?	MmPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	M3fYV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwMkO1NFEh\|ryPLh?=	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KOSC-2	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{PWRmlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjR2Nk[yJO69VS5?	M165cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
COR-L88	MkLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2CyVGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy52N{W4N{DPxE1w	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
PSN1	M2nq[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NET3UY5KdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOTB6MEWg{txONg>?	MmTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
LXF-289	MmfWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEfQPWxKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMkG3OkDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
MN-60	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4XWcWlvcGmkaYTpc44hd2ZiaIXtZY4hVU5vNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOzd4MkOg{txONg>?	NF3GOJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NEC8	NXzwWHFYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF7TWoVKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPDdyN{[g{txONg>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H2405	M4jnVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1KyeWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Lke0OFk{KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
YH-13	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoTuTY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE44PTd5NjFOwG0v	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SK-MEL-2	M3HsR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXnVfVhrUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNT6wPVY{OiEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NB13	M3jMPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF\2UoJKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvOzJ5OE[g{txONg>?	MmfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
GAMG	MonWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXO0S4NMUW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjN5MUWg{txONg>?	NWKwdoFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1792	NFrvUFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml;1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwNEe5OVQh\|ryPLh?=	M{ju[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KP-4	NF;sZ2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4fMOGlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU43QTh{MzFOwG0v	M1rmbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HGC-27	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jNW2lvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2Njd\|MEe3JO69VS5?	M2LlWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
GCT	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnzaTY5pcWKrdHnvckBw\iCqdX3hckBIS1RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuPFUyOjFizszNMi=>	M4X2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
PFSK-1	NVz4R\|Z3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXzJcohq[mm2aX;uJI9nKGi3bXHuJHBHW0tvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU45PjF4ODFOwG0v	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
A172	M17BSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVTsV253UW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjlyN{mg{txONg>?	NYPEOolIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	M3[5[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFjnbZBKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3Lkm1OFI2KM7:TT6=	NFLqV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HN	MkG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHrLXW5KdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1Mlk4ODl5IN88UU4>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
IST-MES1	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGLOU5dKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3NSXMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3Lkm3OVIyKM7:TT6=	MnLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
TGW	NW\zUHVbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4fCSmlvcGmkaYTpc44hd2ZiaIXtZY4hXEeZIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlA2Pjh{IN88UU4>	NYTHXWgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
COR-L23	M3Tac2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3LCc2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi5\|N{O1JO69VS5?	M4PNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
D-566MG	M{T2cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWnOOVltUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB4Lke4PFc{KM7:TT6=	M4H2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SKG-IIIa	NFzvcm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3jlUmlvcGmkaYTpc44hd2ZiaIXtZY4hW0uJLVnJTYEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDZwOEW1O\|Ih\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H446	NX\XbFB2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4GzdmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OFYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMEG4NUDPxE1w	M1LGcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KYSE-270	M{nMfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1roR2lvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2yO\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMEO4O\|Ih\|ryPLh?=	Mo[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
CAL-39	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWmzdpFWUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwM{WyOEDPxE1w	NFzVOHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
IST-SL1	NEf4OYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFfo[ZNKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwNEOzOFkh\|ryPLh?=	MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SF539	NYXUeJJyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHTXU5hKdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjV3MUm3JO69VS5?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
TE-1	MnXMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHXSZ2FKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvQDlyOUGg{txONg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NB10	M{TRc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHH4cVVKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvQTh5NUig{txONg>?	Ml3tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
8505C	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFy4RnNKdmirYnn0bY9vKG:oIHj1cYFvKDh3MEXDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4Njl7OEG3JO69VS5?	NV3pWoxURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
DB	NUXtO2hTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF:wflBKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlAyOTNzIN88UU4>	NG\rOYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H28	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvPTl6OESg{txONg>?	NH7Ob409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
LOXIMVI	M33EVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvPjN5MEGg{txONg>?	NYDrUZcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
ME-180	NY\UfVJIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWrmOWhHUW6qaXLpeIlwdiCxZjDoeY1idiCPRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDhwOECzPVUh\|ryPLh?=	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
ES3	MnvvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEXx[JJKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU4yOjd7NDFOwG0v	NU\ESphFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SK-N-FI	NXLJcIE{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGjPcVdKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDlwNEG2PVkh\|ryPLh?=	MoLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NBsusSR	Ml:xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIP4NGZKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkKzNVgh\|ryPLh?=	NYjyc3puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
GI-ME-N	M2[xXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3XrZWlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvTVWtUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwMke4N{DPxE1w	NVjTXZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A704	M1vzTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGr6SVJKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjN\|MUig{txONg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HuP-T4	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4fRfWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC52MkexJO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
A101D	M{nIXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGXtRYxKdmirYnn0bY9vKG:oIHj1cYFvKEFzMEHEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5zNUe0JO69VS5?	MlXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
MCF7	NV;heGNtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4HVVWlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvOTh2OTFOwG0v	NV;2VFZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A549	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV\EdYpiUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5{ME[g{txONg>?	NWPOS2hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HD-MY-Z	M1THVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWDRcot7UW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT6yNFYh\|ryPLh?=	NXToT\|lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HCC1395	MkfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF\|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjV3OU[g{txONg>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SK-NEP-1	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFfjPFVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT63N\|MzKM7:TT6=	NFjQOYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HSC-2	NITKRVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mlf3TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvPzh2MjFOwG0v	NXHOXnBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HCC1937	NYOyZodGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUjobXZDUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPVM4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT64OFc{KM7:TT6=	NELWTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RS4-11	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NE\TfZlKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwOEizOkDPxE1w	NV3WNXBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
CAL-27	NXviTWVkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmnyTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjF4M{eg{txONg>?	NXfKSY9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H23	NIC0bIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3LXd2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTJwNEG1OUDPxE1w	Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A431	NFGxOJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmjUTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNk44OjN\|IN88UU4>	NILucIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HT-1080	MmT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4n2dmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTJwN{O3N{DPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
GB-1	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlK4TY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNk44PzF4IN88UU4>	M3r1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
BFTC-909	NGXyNIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy5zME[4JO69VS5?	M3;E[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
CAL-33	NH\kSI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnTSTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjZ3MUig{txONg>?	NVPSUHQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
JVM-3	NFLvfXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFfPRZNKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC5{NkK3JO69VS5?	NGC2S5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
AN3-CA	NUfFeJBXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NELvZohKdmirYnn0bY9vKG:oIHj1cYFvKEGQMz3DRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTRwOUW3PEDPxE1w	MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	NGLUd\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml\hTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTVwMUO2OEDPxE1w	NGfnepc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
A253	MnLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG1MlI5OzRizszNMi=>	NEnkXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RPMI-7951	NXHsUWhLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXrJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwMUm4NUDPxE1w	NVThXHhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1563	NXvKd4RtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWexcWdNUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG2MlgzPTNizszNMi=>	MmHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
LB831-BLC	M4jqVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWHJUXVTUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG3MlE6OjlizszNMi=>	NVzVTVlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
ES8	NE\vPFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\TOZBIUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE4NjNzNUeg{txONg>?	NXvDO5J7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H292	M1zNUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPy52N{S5JO69VS5?	NIDXXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
OAW-42	MmjaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF;YUINKdmirYnn0bY9vKG:oIHj1cYFvKE:DVz20NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTdwOEiyN{DPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
RCC10RGB	Moj4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlvrTY5pcWKrdHnvckBw\iCqdX3hckBTS0NzMGLHRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTdwOUW3PEDPxE1w	NEey[3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
PC-3	Mlq4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlTsTY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE4xODR\|IN88UU4>	MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HCC38	M1;mbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{fNSGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFM{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5NjFyM{Gg{txONg>?	NVHqdnd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
DEL	M4LKVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFTiO\|JKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOzh5IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ABC-1	NUjtRYlsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYHJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE42PjJ5IN88UU4>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SW756	NI\NUGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NELTPVBKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS5zM{WxJO69VS5?	M1OzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
TE-6	M372Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX[zXXdDUW6qaXLpeIlwdiCxZjDoeY1idiCWRT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS5{MUCzJO69VS5?	NWfoc5drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
H-EMC-SS	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3XZb2lvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF7LkSzOVkh\|ryPLh?=	M4XpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HCT-116	M{XkcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnjoTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS54Nkig{txONg>?	NEXPWnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CHP-212	NXTUbGNMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{m2WGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTlwN{S3PEDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SK-LU-1	M4DOcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6Njd3MzFOwG0v	NXnadZJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HT-3	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFu4TldKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjB{ODFOwG0v	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KG-1	M1zoOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVy2XW01UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOC5{ME[g{txONg>?	NYLWfHBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
ES1	NUHlRYl4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmjSTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKxMlAxPDhizszNMi=>	M1\1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M{nYO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGPq[FFKdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS55N{W2JO69VS5?	M1fHRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
IA-LM	MofuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFnFTYNKdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS57Nkm0JO69VS5?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
BHT-101	NIjmS3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoLyTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOi5yNkK5JO69VS5?	NFrIb5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
OVCAR-4	NGfG[VBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX7qdIhyUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mj60O{DPxE1w	MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SW1573	NH2zVnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXrJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTV5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlIvPzl\|NDFOwG0v	NHX0PXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CHL-1	NHSyS2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyN{4zQDN\|IN88UU4>	NE\FO5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
BFTC-905	NVHpVWVKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEHhbVdKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mz6yPFkzKM7:TT6=	NF3UepE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
TE-12	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGCweGRKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy53N{iyJO69VS5?	NV;ZS3hJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H358	NH7yWplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{nVSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVizOVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ\|Lk[0O\|ch\|ryPLh?=	MliwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
OVCAR-5	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmG0TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPC5zMESg{txONg>?	NGnFPYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CGTH-W-1	NUfoS2hKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS5yOEC0JO69VS5?	Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SNU-423	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoXJTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS5\|Nk[g{txONg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	M1SyWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWjNNnBbUW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU44Ozl7IN88UU4>	Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2087	M2SweGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWDNSmh{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1Mlg3PTVizszNMi=>	M33tUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
RMG-I	M1PlcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1nX[mlvcGmkaYTpc44hd2ZiaIXtZY4hWk2JLVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI2Njl{MUmg{txONg>?	NF7VepM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
KP-N-YS	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHLsPYVKdmirYnn0bY9vKG:oIHj1cYFvKEuSLV6tXXMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ4LkKwNkDPxE1w	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
OMC-1	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG9OSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOk42ODhizszNMi=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
DMS-114	NIDCSZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1fhfWlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUGxOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjdwM{m2OkDPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SHP-77	NGL1WlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NViweJM4UW6qaXLpeIlwdiCxZjDoeY1idiCVSGCtO\|ch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5LkS4PEDPxE1w	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
MPP-89	NUTuOIlPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWHVXFI1UW6qaXLpeIlwdiCxZjDoeY1idiCPUGCtPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5Lkm0N\|gh\|ryPLh?=	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1581	MlPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHv3UI1KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU5OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkiuOFU{PSEQvF2u	NXTZcIxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
D-283MED	NIDoNnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NU[ySnF5UW6qaXLpeIlwdiCxZjDoeY1idiCGLUK4N21GTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkiuOFY4PCEQvF2u	M{PDT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
MOLT-4	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlgvQTB5MjFOwG0v	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ES6	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGVUPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkmuOlQ{PiEQvF2u	NV7LbGN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NB6	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1;KOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPU45PjN6IN88UU4>	NGHWRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SW954	NYnsb2NST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH72[XVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQS57NEC3JO69VS5?	M1[yelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
A388	NHKxNllIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFHneo5KdmirYnn0bY9vKG:oIHj1cYFvKEF\|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI6Njl2MkKg{txONg>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
OAW-28	Ml;US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFPsPVdKdmirYnn0bY9vKG:oIHj1cYFvKE:DVz2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzBwMkK3PEDPxE1w	MoToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NYGwNXRZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{G3[GlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNzLkKyNFgh\|ryPLh?=	NGX1VZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H441	NF[4OnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNESxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS57OE[4JO69VS5?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HOP-92	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC17MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvOjN3NjFOwG0v	NH;a[oo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NB14	M1vCdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1;re2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvPzJ3MTFOwG0v	NWPod5VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MS-1	NITSSYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3STY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk44PjB2IN88UU4>	NXHkbWM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
YKG-1	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk45OzN4IN88UU4>	MkX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SiHa	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEXiR3BKdmirYnn0bY9vKG:oIHj1cYFvKFOrSHGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM{NjN6Mkmg{txONg>?	M2TzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HAL-01	M1WwO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYnFd5I4UW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2LkKzO\|Yh\|ryPLh?=	M3PkSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
Ca-Ski	M3zP[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWjSd4RlUW6qaXLpeIlwdiCxZjDoeY1idiCFYT3Tb4kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2Lke2Olkh\|ryPLh?=	M4DkUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H747	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHXjcHpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|ND65PFc2KM7:TT6=	NWKw[FhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
KYSE-510	M3KxR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVrVUG4yUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVUyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{WuOlQ5PSEQvF2u	NWfZ[3NJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A204	NWLUZ5pTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYnsXZh{UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PS55MkC5JO69VS5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HSC-3	NVvqRXB[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzOk4xODh4IN88UU4>	NXLCPXhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HuP-T3	NELEV3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml7VTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM3NjR6M{Kg{txONg>?	M{LyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
RPMI-8226	NVzHXIpHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwNkKwPEDPxE1w	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NHryN2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEe2fVdKdmirYnn0bY9vKG:oIHj1cYFvKFGLTWKtW2lNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Nj62OFQh\|ryPLh?=	NXrlbYs6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HuH-7	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGh2UC15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzPE43OTh2IN88UU4>	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
CAL-12T	NWq0b3Z{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIPnNpJKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN6Lkm0NVYh\|ryPLh?=	NWOxdmdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
GT3TKB	M2n4eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHjC[JpKdmirYnn0bY9vKG:oIHj1cYFvKEeWM2TLRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzlwMUmyNUDPxE1w	M4TkNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
OC-314	M{DCSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXe5UFN1UW6qaXLpeIlwdiCxZjDoeY1idiCRQz2zNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkexNlUh\|ryPLh?=	NXTZXpdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H2228	M3qxT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIrWU4VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlIzQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNECuNVQxOyEQvF2u	MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H727	NVfwWJR5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1XsSmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRyLkK1N\|Eh\|ryPLh?=	M3zHZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	NFfsRo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnLpTY5pcWKrdHnvckBw\iCqdX3hckBPXEWUQT3TMYNtNURzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0NE41PzB4IN88UU4>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
MMAC-SF	NFnyWYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEHGW3RKdmirYnn0bY9vKG:oIHj1cYFvKE2PQVOtV2Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRyLkmyN\|Uh\|ryPLh?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HTC-C3	MnjTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGLPfYtKdmirYnn0bY9vKG:oIHj1cYFvKEiWQz3DN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwNEG2PUDPxE1w	NGrVdGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SF295	MmnoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1rSeWlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQyNjV\|N{mg{txONg>?	M3PjWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
U-2-OS	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4LNN2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS56NU[3JO69VS5?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HPAF-II	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkjYTY5pcWKrdHnvckBw\iCqdX3hckBJWEGILVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS57M{iyJO69VS5?	M1TpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KYSE-450	M3vV[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEX1bHBKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mj60O\|A4KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
DMS-273	Ml\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NITX[lFKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR\|LkK4N\|Yh\|ryPLh?=	MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HT-1376	NFy0RlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF\|N{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ{NjNzNU[g{txONg>?	NV6xdZc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
786-0	M{juZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFHoT5lKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oy54Mk[xJO69VS5?	M1nMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H810	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PC5yMUO2JO69VS5?	Mlj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
8305C	MlvRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFPpdpdKdmirYnn0bY9vKG:oIHj1cYFvKDh\|MEXDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PC54NEWg{txONg>?	M120d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
DSH1	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1zPS2lvcGmkaYTpc44hd2ZiaIXtZY4hTFOKMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFUvPzB2MjFOwG0v	MlLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KYSE-520	MnqxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYTqfI1VUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVUzOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNE[uOVczOSEQvF2u	NEDyfWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
TYK-nu	NEXJRoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH;4[4xKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{C5NkDPxE1w	NEXvdG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
EPLC-272H	MnjJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIfGdmlKdmirYnn0bY9vKG:oIHj1cYFvKEWSTFOtNlczUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNE[uO\|I5OyEQvF2u	Mnf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
T-24	NIjocFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIfFUoNKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ4Njl{OUKg{txONg>?	NWDDWpFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
BHY	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGJJYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEeuPVk6KM7:TT6=	M4fjWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H82	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn3aTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QC5{MUeg{txONg>?	MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SF268	MnjVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnEWYtKdmirYnn0bY9vKG:oIHj1cYFvKFOIMk[4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QC54MUi5JO69VS5?	NUjGc41oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
C-33-A	M2PWbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYrJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFgvPzV3NDFOwG0v	NXHXe3J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	NILD[GZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVf3NFBjUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PE45Ozh6IN88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HCC1954	NVW4UlgzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjB6N{Gg{txONg>?	Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1666	NXvPZXB5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWDPVolIUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES5MlM3PDJizszNMi=>	M3[1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
GR-ST	M{XmUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3LNOWlvcGmkaYTpc44hd2ZiaIXtZY4hT1JvU2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjN4OUWg{txONg>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
Ca9-22	Ml;vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFkvPDBzMzFOwG0v	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
D-502MG	NGXyfm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUjZdXhyUW6qaXLpeIlwdiCxZjDoeY1idiCGLUWwNm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2OT60NVch\|ryPLh?=	NX;SNVlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SCC-4	M4HDbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIXyfmtKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS53NkCyJO69VS5?	NFLlTVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RKO	NHHycIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWXJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEmuPFM2PiEQvF2u	MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.	27385216
Immunofluorescence	PARP1 / Plk1 ; PubMed: 28069876 Mol Cancer Ther Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.	28069876
Growth inhibition assay	Cell viability; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3.	27385216

Protocol

Kinase Assay:^[1]

- Collapse

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

- Collapse

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC2=C(C=CC(=C2)C=C3C(=O)NC(=NCC4=CC=CS4)S3)N=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306